India, July 11 -- image credit- freepik

The Indian GLP-1 agonist market has grown into a Rs 2,055 crore segment as of the moving annual total (MAT) ending June 2026, driven by rapid adoption of newer therapies for diabetes and obesity. However, after two years of exceptional expansion, the market is showing early signs of stabilisation as the pace of growth moderates, according to the latest data from Pharmarack Technologies.

The GLP-1 agonist market expanded from Rs 135 crore in MAT June 2022 to Rs 272 crore in June 2023, Rs 467 crore in June 2024, Rs 608 crore in June 2025, before surging to Rs 2,055 crore in MAT June 2026. This represents a remarkable transformation in India's diabetes and obesity treatment landscape, with the market...